In the primary analysis of the phase 2 ROSEWOOD trial, combination zanubrutinib and obinutuzumab (ZO) demonstrated superior overall response rate (ORR) and progression-free survival (PFS) compared with obinutuzumab monotherapy (O) in patients with relapsed/refractory follicular lymphoma (R/R FL) who had received ≥ 2 prior lines of therapy. To report the final analysis of ROSEWOOD with a median follow-up of 34.6 months. Patients with R/R FL were randomised 2:1 to receive ZO or O. Efficacy endpoints included ORR, duration of response (DoR), PFS, overall survival (OS) and time to next anticancer therapy or crossover (TTNT); safety was also assessed. ZO maintained superior ORR versus O (70.3
Extrapulmonary neuroendocrine carcinoma (epNEC) is a term that describes a group of rare, heterogeneous, and aggressive cancers. Because epNECs can have varying sites of origin, patients are often treated by a broad range of specialties, which can lead to challenges in diagnosis, referral, and prompt initiation of treatment. Furthermore, epNECs are often diagnosed when the disease is already metastatic. Currently, no treatments are specifically approved for epNEC and standard first-line treatment involves platinum-based chemotherapy. Cytotoxic chemotherapy and immunotherapy are often utilized for refractory disease but have limited benefits. Effective disease-specific treatments are needed. In this podcast, we discuss the patient journey associated with epNEC. We provide a brief introduction to the epidemiology and disease characteristics of epNEC, followed by discussions about diagnosis and treatment, highlighting challenges and unmet needs from the perspectives of a medical oncologist, patient, caregiver, and patient advocacy group founder. We also highlight the vital role played by patient advocacy groups in raising awareness, providing educational resources, and facilitating peer support. Overall, the journey for patients with epNEC could be improved by increasing awareness among healthcare providers, improving access to specialist centers, and developing novel targeted treatments. The podcast and transcript can be viewed below the abstract of the online version of the article. Alternatively, the podcast can be downloaded here: https://doi.org/10.6084/m9.figshare.34068396 .
Radium-223 dichloride (radium-223) is an α-emitting radionuclide approved for treating metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases and no visceral disease. Although efficacy and safety were established in pivotal trials, real-world evidence in Asian populations, particularly Taiwan, remains limited. Here we report the final analysis of the observational RAdium-223 dichloride in routine clinical Practice settings In Taiwan (RAPIT) study. This prospective, multicenter, single-arm, noninterventional study included patients with mCRPC with symptomatic bone metastases receiving radium-223 in clinical practice in Taiwan. The primary objective was to evaluate safety, including treatment-emergent and drug-related adverse events and long-term safety. Effectiveness outcomes were secondary endpoints. A total of 224 patients were enrolled; most had ≤ 20 bone metastases (69.2
Randomized trials have established the efficacy of adjuvant and neoadjuvant immunotherapy in resectable stage III melanoma, yet how these findings translate into real-world practice remains unclear. Using the National Cancer Database (NCDB), we evaluated treatment patterns and survival outcomes among 14,164 patients with clinical stage III melanoma treated with surgery alone, adjuvant immune checkpoint inhibitors (ICI), adjuvant targeted therapy, neoadjuvant immunotherapy, or neoadjuvant targeted therapy. Of the 14,164 patients, 6889 (48.6
Poly(ADP-ribose) polymerase (PARP) inhibitors are established treatment options for patients with germline BRCA1/2-mutated hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer. However, evidence regarding their optimal sequencing after cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor-based therapy remains limited. To evaluate the real-world efficacy and safety of olaparib after prior CDK4/6 inhibitor plus endocrine therapy, with particular emphasis on treatment sequence and line of olaparib use. This multicenter real-world retrospective study included patients with HR+/HER2− metastatic breast cancer harboring germline BRCA1/2 pathogenic variants who received olaparib after prior CDK4/6 inhibitor plus endocrine therapy. We retrospectively collected clinical characteristics, treatment sequence, response, survival outcomes, and olaparib-related adverse events. We evaluated progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events. We included 52 patients from 28 institutions. Median age at olaparib initiation was 49.9 years [interquartile range (IQR), 40.2–59.0 years], and median follow-up was 12.84 months (95
